# Immunomodulatory Mechanism of Baiyaojian Decoction on Periodontitis: Network Pharmacology, Single‐Cell RNA Sequencing and Molecular Docking

**Authors:** Bing‐jun Chen, Ming‐ming Li, Zhao‐yu Zheng, Wen‐qin Jin, Zhao Jin, Yu‐ling Zuo

PMC · DOI: 10.1111/jcmm.71034 · 2026-01-28

## TL;DR

This study explores how Baiyaojian decoction treats periodontitis by analyzing its immunomodulatory effects using network pharmacology, single-cell RNA sequencing, and molecular docking.

## Contribution

The study reveals the multi-ingredient and multi-target mechanisms of Baiyaojian decoction in modulating immune cells in periodontitis.

## Key findings

- Baiyaojian decoction's 27 active ingredients target 207 proteins, with 31 core therapeutic targets identified.
- Immune cell infiltration, including plasma cells and macrophages, is significantly enhanced in periodontitis tissues.
- Key ingredients like Coumestrol and Diosmetin show anti-inflammatory effects and stable binding to therapeutic targets.

## Abstract

Periodontitis is one of the most common oral inflammatory diseases. Baiyaojian decoction, known for its prominent immunomodulatory and anti‐inflammatory properties, shows significant potential in treating periodontitis, though its molecular mechanisms remain unknown. The active ingredients and therapeutic targets were determined by integrating multiple databases. The protein–protein interaction network was constructed by the STRING platform. Bulk RNA seq data of GSE16134 were included and GO enrichment, GSEA and CIBERSORT algorithm were employed to investigate the immune microenvironment in periodontitis. Single‐cell RNA seq data of GSE152042 and GSE171213 were integrated by harmony; the cell–cell communication network was analysed by CellChat, and the differentiation trajectory was constructed by monocle3. Molecular docking was carried out using AutoDockTools, AutoDock Vina and PyMOL. Experimental validation was performed via qRT‐PCR, CCK‐8 assay, flow cytometry and ELISA. Twenty‐seven active ingredients and 207 therapeutic targets were obtained. Thirty‐one core therapeutic targets were identified. The infiltration of plasma cells, neutrophils, macrophages and mast cells was significantly enhanced in periodontitis tissues. Twenty‐eight of 31 core therapeutic targets were involved in their infiltration, differentiation and pro‐inflammatory activities. Molecular docking suggested stable bindings between ingredients and therapeutic targets. Experimental validation confirmed the elevated infiltration of above immune cells and demonstrated the anti‐inflammatory properties and target modulation capabilities of key ingredients including Coumestrol, Diosmetin and Gallicin. Baiyaojian decoction may exert immunomodulatory and anti‐inflammatory effects to treat periodontitis through multi‐ingredient and multi‐target mechanisms.

## Linked entities

- **Chemicals:** Coumestrol (PubChem CID 5281707), Diosmetin (PubChem CID 5281612), Gallicin (PubChem CID 7428)
- **Diseases:** periodontitis (MONDO:0005076)

## Full-text entities

- **Genes:** Mmp8 (matrix metallopeptidase 8) [NCBI Gene 17394], IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, ITGA2 (integrin subunit alpha 2) [NCBI Gene 3673] {aka BR, CD49B, FMAIT3, GPIa, HPA-5, VLA-2}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313] {aka CLG4, CLG4A, MMP-2, MMP-II, MONA, TBE-1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, Tnfsf11 (tumor necrosis factor (ligand) superfamily, member 11) [NCBI Gene 21943] {aka Ly109l, ODF, OPGL, RANKL, Trance}, Kdr (kinase insert domain protein receptor) [NCBI Gene 16542] {aka 6130401C07, Flk-1, Flk1, Krd-1, Ly73, VEGFR-2}, PTK2 (protein tyrosine kinase 2) [NCBI Gene 5747] {aka FADK, FADK 1, FAK, FAK1, FRNK, PPP1R71}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, PARP1 (poly(ADP-ribose) polymerase 1) [NCBI Gene 142] {aka ADPRT, ADPRT 1, ADPRT1, ARTD1, PARP, PARP-1}, CEBPB (CCAAT enhancer binding protein beta) [NCBI Gene 1051] {aka C/EBP-beta, IL6DBP, NF-IL6, TCF5}, Stat1 (signal transducer and activator of transcription 1) [NCBI Gene 20846] {aka 2010005J02Rik}, Casp3 (caspase 3) [NCBI Gene 12367] {aka A830040C14Rik, AC-3, CASP-3, CC3, CPP-32, CPP32}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932], EDIL3 (EGF like and discoidin domains 3) [NCBI Gene 10085] {aka DEL1}, Jak2 (Janus kinase 2) [NCBI Gene 16452] {aka Fd17}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Ptgs2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 19225] {aka COX2, Cox-2, PES-2, PGHS-2, PHS II, PHS-2}, Mmp9 (matrix metallopeptidase 9) [NCBI Gene 17395] {aka B/MMP9, Clg4b, Gel B, MMP-9, pro-MMP-9}, Cxcl15 (C-X-C motif chemokine ligand 15) [NCBI Gene 20309] {aka Il8, Scyb15, lungkine, weche}, Mrgprx2 (MAS-related GPR, member X2) [NCBI Gene 243978] {aka G370024M05Rik, MrgB10, Mrgprb10}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}
- **Diseases:** chronic gastritis (MESH:D005756), autoimmune disease (MESH:D001327), Periodontitis (MESH:D010518), osteoarthritis (MESH:D010003), gum atrophy (MESH:C537732), immune dysregulation (OMIM:614878), rheumatoid arthritis (MESH:D001172), alveolar bone loss (MESH:D016301), ulcerative colitis (MESH:D003093), cancers (MESH:D009369), fibrosis (MESH:D005355), cytotoxic (MESH:D064420), pro-inflammatory cytokines (MESH:D000080424), diabetes (MESH:D003920), non-alcoholic fatty liver disease (MESH:D065626), bone loss (MESH:D001847), atherosclerosis (MESH:D050197), DR (MESH:D003930), cardiovascular disease (MESH:D002318), respiratory diseases (MESH:D012140), bone resorption (MESH:D001862), colorectal cancer (MESH:D015179), chronic kidney disease (MESH:D051436), oral diseases (MESH:D009059), lung inflammation (MESH:D011014), attachment loss (MESH:D017622), inflammation (MESH:D007249)
- **Chemicals:** NO (MESH:D009614), lithium chloride (MESH:D018021), polyphenol (MESH:D059808), Decursin (MESH:C101278), Baiyaojian (-), prim-O-glucosylcimifugin (MESH:C498945), Tetracycline (MESH:D013752), Coumestrol (MESH:D003375), diacylglycerol (MESH:D004075), Gallotannins (MESH:D047348), Diosmetin (MESH:C039602), Taraxacin (MESH:C413041), ROS (MESH:D017382), Curcumin (MESH:D003474), taraxasterol (MESH:C079988), flavonoid (MESH:D005419), I (MESH:D007455), CO2 (MESH:D002245), Doxycycline (MESH:D004318), LPS (MESH:D008070), CCK-8 (MESH:D012844), triacylglycerol (MESH:D014280)
- **Species:** Fusobacterium nucleatum (species) [taxon 851], Streptococcus (genus) [taxon 1301], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Saposhnikovia divaricata (species) [taxon 203717], Porphyromonas gingivalis (species) [taxon 837], Taraxacum (genus) [taxon 49743]
- **Cell lines:** RAW 264.7 — Mus musculus (Mouse), Mouse leukemia, Cancer cell line (CVCL_0493)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12851902/full.md

---
Source: https://tomesphere.com/paper/PMC12851902